Compare
AbbVie vs ADMA Biologics (ABBV vs ADMA)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and ADMA Biologics (ADMA) -17.2%; so far this year the figures are +27.5% and -30.2%.
AbbVie is the larger company by market value, about 182.6 times the size of ADMA Biologics.
On trailing earnings, ABBV trades at 50.1 times and ADMA at 16.5 times.
Revenue grew +10.7% at ABBV and +6.3% at ADMA over the last year.
ABBV yields 2.38%. ADMA pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | ADMA | |
|---|---|---|
| Price | $291.31 | $12.73 |
| 1-day | +1.07% | -3.63% |
| YTD | +27.49% | -30.21% |
| 1 year | +34.39% | -17.18% |
| 3 years | +104.47% | +261.65% |
| Market cap | $514.9B | $2.8B |
| P/E | 50.1 | 16.5 |
| P/S | 7.80 | 5.44 |
| P/B | — | 6.44 |
| Revenue growth | +10.70% | +6.30% |
| EPS growth | +340.20% | -10.50% |
| Gross margin % | 73.7 | 68.5 |
| Net margin % | 15.7 | 35.1 |
| ROE % | — | 41.6 |
| Debt / equity | — | 0.45 |
| FCF yield % | 3.7 | 4.7 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.07 |
| RSI (14) | 59.7 | 65.8 |
| Technical rating |